LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 71

Search options

  1. Article ; Online: Removal of common antimicrobial agents by sustained low-efficiency dialysis.

    Hudson, Joanna Q / Hilgers, Madelyn N / Gosmanova, Elvira O

    Antimicrobial agents and chemotherapy

    2024  Volume 68, Issue 3, Page(s) e0157923

    Abstract: Adequate dosing of antimicrobials is paramount for treating infections in critically ill patients undergoing kidney replacement therapy; however, little is known about antimicrobial removal by sustained low-efficiency dialysis (SLED). The objective was ... ...

    Abstract Adequate dosing of antimicrobials is paramount for treating infections in critically ill patients undergoing kidney replacement therapy; however, little is known about antimicrobial removal by sustained low-efficiency dialysis (SLED). The objective was to quantify the removal of cefepime, daptomycin, meropenem, piperacillin-tazobactam, and vancomycin in patients undergoing SLED. Adult patients ≥18 years with acute kidney injury (AKI) or end-stage kidney disease receiving one of the select antimicrobials and requiring SLED were included. Blood and dialysate flow rates were maintained at 250 and 100 mL/min, respectively. Simultaneous arterial and venous blood samples for the analysis of antibiotic concentrations were collected hourly for 8 hours during SLED (on-SLED). Arterial samples were collected every 2 hours for up to 6 hours while not receiving SLED (off-SLED) for the calculation of SLED clearance, half-life (
    MeSH term(s) Adult ; Humans ; Male ; Middle Aged ; Aged ; Female ; Meropenem/therapeutic use ; Vancomycin/therapeutic use ; Cefepime/therapeutic use ; Hybrid Renal Replacement Therapy ; Daptomycin/therapeutic use ; Renal Dialysis ; Anti-Bacterial Agents ; Piperacillin, Tazobactam Drug Combination/therapeutic use ; Critical Illness ; Acute Kidney Injury/drug therapy ; Retrospective Studies
    Chemical Substances Meropenem (FV9J3JU8B1) ; Vancomycin (6Q205EH1VU) ; Cefepime (807PW4VQE3) ; Daptomycin (NWQ5N31VKK) ; Anti-Bacterial Agents ; Piperacillin, Tazobactam Drug Combination (157044-21-8)
    Language English
    Publishing date 2024-02-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 217602-6
    ISSN 1098-6596 ; 0066-4804
    ISSN (online) 1098-6596
    ISSN 0066-4804
    DOI 10.1128/aac.01579-23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Response to the Letter from Gay and Kolkhof.

    Gosmanova, Elvira O

    Current hypertension reports

    2017  Volume 19, Issue 9, Page(s) 75

    MeSH term(s) Humans ; Hypertension ; Kidney Failure, Chronic ; Receptors, Mineralocorticoid
    Chemical Substances Receptors, Mineralocorticoid
    Language English
    Publishing date 2017-08-16
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2057367-4
    ISSN 1534-3111 ; 1522-6417
    ISSN (online) 1534-3111
    ISSN 1522-6417
    DOI 10.1007/s11906-017-0773-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: A generic method for analysis of plasma concentrations
.

    Phelps, Kenneth R / Gosmanova, Elvira O

    Clinical nephrology

    2020  Volume 94, Issue 1, Page(s) 43–49

    Abstract: The purpose of this NephEd contribution is to introduce a generic method for analyzing plasma concentrations ([ ...

    Abstract The purpose of this NephEd contribution is to introduce a generic method for analyzing plasma concentrations ([
    MeSH term(s) Biomarkers/blood ; Biomarkers/metabolism ; Biomarkers/urine ; Creatinine/blood ; Creatinine/metabolism ; Creatinine/urine ; Glomerular Filtration Rate/physiology ; Humans ; Kidney Function Tests/methods ; Kidney Glomerulus/physiology ; Metabolic Clearance Rate/physiology
    Chemical Substances Biomarkers ; Creatinine (AYI8EX34EU)
    Language English
    Publishing date 2020-05-08
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 185101-9
    ISSN 0301-0430
    ISSN 0301-0430
    DOI 10.5414/CN110056
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Neutrophil gelatinase-associated lipocalin in acute heart failure: time to move on?

    Gosmanova, Elvira O / Lyubarova, Radmila

    European journal of heart failure

    2019  Volume 22, Issue 2, Page(s) 264–266

    MeSH term(s) Acute Kidney Injury ; Biomarkers ; Heart Failure ; Humans ; Lipocalin-2 ; Prognosis
    Chemical Substances Biomarkers ; Lipocalin-2
    Language English
    Publishing date 2019-12-21
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 1483672-5
    ISSN 1879-0844 ; 1388-9842
    ISSN (online) 1879-0844
    ISSN 1388-9842
    DOI 10.1002/ejhf.1684
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Determinants of the serum phosphate concentration in chronic kidney disease.

    Gosmanova, Elvira O / Gemoets, Darren E / Dharia, Sunny / Der Mesropian, Paul / Shaikh, Gulvahid / Kovesdy, Csaba P / Phelps, Kenneth R

    Clinical nephrology

    2023  Volume 101, Issue 2, Page(s) 82–92

    Abstract: ... If ... ...

    Abstract If C
    MeSH term(s) Humans ; Phosphates ; Creatinine ; Renal Dialysis ; Renal Insufficiency, Chronic ; Glomerular Filtration Rate
    Chemical Substances Phosphates ; Creatinine (AYI8EX34EU)
    Language English
    Publishing date 2023-12-12
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 185101-9
    ISSN 0301-0430
    ISSN 0301-0430
    DOI 10.5414/CN111260
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Novel Approaches for Assessment of Bone Turnover in CKD: Is New Always Better?

    Gosmanova, Elvira O / Gosmanov, Aidar R

    Journal of the American Society of Nephrology : JASN

    2018  Volume 29, Issue 9, Page(s) 2443

    MeSH term(s) Biomarkers ; Bone Remodeling ; Chronic Kidney Disease-Mineral and Bone Disorder ; Humans ; Parathyroid Hormone ; Renal Insufficiency, Chronic
    Chemical Substances Biomarkers ; Parathyroid Hormone
    Language English
    Publishing date 2018-07-30
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1085942-1
    ISSN 1533-3450 ; 1046-6673
    ISSN (online) 1533-3450
    ISSN 1046-6673
    DOI 10.1681/ASN.2018050561
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Patient-Centered Approach for Hypertension Management in End-Stage Kidney Disease: Art or Science?

    Gosmanova, Elvira O / Kovesdy, Csaba P

    Seminars in nephrology

    2018  Volume 38, Issue 4, Page(s) 355–368

    Abstract: Hypertension is present in most patients with end-stage kidney disease initiating dialysis and management of hypertension is a routine but challenging task in everyday dialysis care. End-stage kidney disease patients are uniquely heterogeneous ... ...

    Abstract Hypertension is present in most patients with end-stage kidney disease initiating dialysis and management of hypertension is a routine but challenging task in everyday dialysis care. End-stage kidney disease patients are uniquely heterogeneous individuals with significant variations in demographic characteristics, functional capacity, and presence of concomitant comorbid conditions and their severity. Therefore, these patients require personalized approaches in addressing not only hypertension but related illnesses, while also accounting for overall prognosis and projected longevity. There are only limited clinical trial data to guide individualized blood pressure management and current guidelines are based predominantly on observational evidence and expert opinions. Inthis review, we reflect on the shortcomings of peridialytic blood pressure recordings and discuss an important paradigm shift toward using out-of-dialysis blood pressure for evaluating hypertension control and for making treatment decisions. In addition, we provide our personal view on blood pressure goals and summarize nonpharmacologic and pharmacologic treatment options for individualized management of hypertension in end-stage kidney disease.
    MeSH term(s) Antihypertensive Agents/therapeutic use ; Blood Pressure Determination ; Blood Pressure Monitoring, Ambulatory ; Comorbidity ; Diet, Sodium-Restricted ; Humans ; Hypertension/epidemiology ; Hypertension/therapy ; Kidney Failure, Chronic/epidemiology ; Kidney Failure, Chronic/therapy ; Patient-Centered Care ; Peritoneal Dialysis/methods ; Renal Dialysis/methods
    Chemical Substances Antihypertensive Agents
    Language English
    Publishing date 2018-08-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604652-6
    ISSN 1558-4488 ; 0270-9295
    ISSN (online) 1558-4488
    ISSN 0270-9295
    DOI 10.1016/j.semnephrol.2018.05.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Recent Trends in Hypoparathyroidism-Related Inpatient and Emergency Department Admissions and Costs in the United States.

    Kaul, Sanjiv / Gosmanova, Elvira O / Castriota, Felicia / Hitchens, Abby / Candrilli, Sean / Parikh, Rohan / Esterberg, Elizabeth / Ayodele, Olulade

    Journal of the Endocrine Society

    2023  Volume 7, Issue 5, Page(s) bvad050

    Abstract: Hypoparathyroidism (HypoPT) is a rare disease associated with high morbidity. Its economic impact is not well understood. This retrospective, cross-sectional study used data from the United States-based National Inpatient Sample and the Nationwide ... ...

    Abstract Hypoparathyroidism (HypoPT) is a rare disease associated with high morbidity. Its economic impact is not well understood. This retrospective, cross-sectional study used data from the United States-based National Inpatient Sample and the Nationwide Emergency Department Sample from 2010 to 2018 to quantify overall trends in number, cost, charges, and length of stay (LOS) for inpatient hospitalizations and number and charges for emergency department (ED) visits for HypoPT-related and for non-HypoPT-related causes. Additionally, the study estimated the marginal effect of HypoPT on total inpatient hospitalization costs and LOS as well as ED visit charges. Over the observed period, a mean of 56.8-66.6 HypoPT-related hospitalizations and 14.6-19.5 HypoPT-related ED visits were recorded per 100 000 visits per year. Over this period, the rate of HypoPT-related inpatient hospitalizations and ED visits increased by 13.5% and 33.6%, respectively. The mean LOS for HypoPT-related hospitalizations was consistently higher than for non-HypoPT-related causes. Total annual HypoPT-related inpatient hospitalization costs increased by 33.6%, and ED visit charges increased by 96.3%. During the same period, the annual costs for non-HypoPT-related hospitalizations and charges for ED visits increased by 5.2% and 80.3%, respectively. In all years, HypoPT-related hospital encounters resulted in higher charges and costs per individual visit than non-HypoPT-related encounters. The marginal effect of HypoPT on inpatient hospitalization costs and LOS, and on ED charges, increased over the period of observation. This study demonstrated that HypoPT was associated with substantial and increasing healthcare utilization in the United States between 2010 and 2018.
    Language English
    Publishing date 2023-04-18
    Publishing country United States
    Document type Journal Article
    ISSN 2472-1972
    ISSN (online) 2472-1972
    DOI 10.1210/jendso/bvad050
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Association of Serum Calcium and Phosphate With Incident Cardiovascular Disease in Patients With Hypoparathyroidism.

    Kaul, Sanjiv / Ayodele, Olulade / Chen, Kristina / Cook, Erin E / Swallow, Elyse / Rejnmark, Lars / Gosmanova, Elvira O

    The American journal of cardiology

    2023  Volume 194, Page(s) 60–70

    Abstract: The pathophysiological basis for the increased incidence of cardiovascular disease in patients with chronic hypoparathyroidism is poorly understood. To evaluate associations between levels of albumin-corrected serum calcium, serum phosphate, and calcium- ... ...

    Abstract The pathophysiological basis for the increased incidence of cardiovascular disease in patients with chronic hypoparathyroidism is poorly understood. To evaluate associations between levels of albumin-corrected serum calcium, serum phosphate, and calcium-phosphate product with the odds of developing cardiovascular events in patients with chronic hypoparathyroidism with ≥1 calcitriol prescription, we conducted a retrospective nested case-control study of patients who developed a cardiovascular event and matched controls without an event. The primary outcome was the instance of cardiovascular events. An electronic medical record database was used to identify 528 patients for the albumin-corrected serum calcium analysis and 200 patients for the serum phosphate and calcium-phosphate product analyses. Patients with ≥67% of albumin-corrected serum calcium measurements outside the study-defined 2.00 to 2.25 mmol/L (8.0 to 9.0 mg/100 ml) range had 1.9-fold higher odds of a cardiovascular event (adjusted odds ratio, 95% confidence interval 1.89, 1.10 to 3.25) compared with patients with <33% of calcium measurements outside the range. Likewise, patients with any serum phosphate measurements above 0.81 to 1.45 mmol/L (2.5 to 4.5 mg/100 ml) had 3.3-fold higher odds (3.26; 1.24 to 8.58), and those with any calcium-phosphate product measurements above 4.40 mmol
    MeSH term(s) Adult ; Humans ; Calcium ; Phosphates ; Parathyroid Hormone ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/complications ; Retrospective Studies ; Case-Control Studies ; Hypoparathyroidism/epidemiology ; Hypoparathyroidism/etiology
    Chemical Substances Calcium (SY7Q814VUP) ; Phosphates ; Parathyroid Hormone ; calcium phosphate (97Z1WI3NDX)
    Language English
    Publishing date 2023-03-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80014-4
    ISSN 1879-1913 ; 0002-9149
    ISSN (online) 1879-1913
    ISSN 0002-9149
    DOI 10.1016/j.amjcard.2023.01.029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84): A retrospective cohort study.

    Rejnmark, Lars / Ayodele, Olulade / Lax, Angela / Mu, Fan / Swallow, Elyse / Gosmanova, Elvira O

    Clinical endocrinology

    2022  Volume 98, Issue 4, Page(s) 496–504

    Abstract: Objective: This study assessed the risk of developing chronic kidney disease (CKD) and decline in estimated glomerular filtration rate (eGFR) over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human ...

    Abstract Objective: This study assessed the risk of developing chronic kidney disease (CKD) and decline in estimated glomerular filtration rate (eGFR) over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) compared with a historical control cohort of patients not treated with rhPTH(1-84).
    Design: Retrospective cohort study of patients with chronic hypoparathyroidism treated with rhPTH(1-84) derived from the REPLACE (NCT00732615), RELAY (NCT01268098), RACE (NCT01297309) and HEXT (NCT01199614, and its continuation study NCT02910466) clinical trials and a historical control cohort who did not receive PTH selected from an electronic medical record database.
    Patients: One hundred and eighteen patients treated with rhPTH(1-84) and 497 patient controls.
    Measurements: Incident CKD was defined as ≥2 eGFR measurements <60 ml/min/1.73 m
    Results: Over the 5-year period, Kaplan-Meier analyses showed that rhPTH(1-84)-treated patients had a significantly lower risk of developing CKD (log-rank p = .002) and a lower risk for a sustained eGFR decline ≥30% from baseline (log-rank p < .001) compared with patients in the control cohort. In adjusted analyses, patients in the rhPTH(1-84)-treated cohort had a 53% lower risk of developing CKD (hazard ratio [HR], 0.47; 95% confidence interval [CI], 0.25-0.87) and a 65% lower risk for sustained eGFR decline ≥30% from baseline (HR, 0.35; 95% CI, 0.13-0.89) compared with controls.
    Conclusions: Patients with chronic hypoparathyroidism treated with rhPTH(1-84) in long-term clinical trials had a significantly lower risk of developing CKD compared with patients in a historical control cohort not treated with rhPTH(1-84).
    MeSH term(s) Humans ; Adult ; Retrospective Studies ; Parathyroid Hormone ; Hypoparathyroidism/drug therapy ; Renal Insufficiency, Chronic ; Glomerular Filtration Rate
    Chemical Substances Parathyroid Hormone
    Language English
    Publishing date 2022-08-28
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 121745-8
    ISSN 1365-2265 ; 0300-0664
    ISSN (online) 1365-2265
    ISSN 0300-0664
    DOI 10.1111/cen.14813
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top